140 related articles for article (PubMed ID: 36319462)
21. The current management and prognosis of acral lentiginous melanoma.
Wells KE; Reintgen DS; Cruse CW
Ann Plast Surg; 1992 Jan; 28(1):100-3. PubMed ID: 1642394
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
23. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
Ishihara K; Saida T; Otsuka F; Yamazaki N;
Int J Clin Oncol; 2008 Feb; 13(1):33-41. PubMed ID: 18307017
[TBL] [Abstract][Full Text] [Related]
24. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America.
Castaneda CA; Torres-Cabala C; Castillo M; Villegas V; Casavilca S; Cano L; Sanchez J; Dunstan J; Calderon G; De La Cruz M; Cotrina JM; Gomez HL; Galvez R; Abugattas J
Clin Transl Oncol; 2017 Dec; 19(12):1478-1488. PubMed ID: 28577153
[TBL] [Abstract][Full Text] [Related]
25. Fine Needle Aspiration Cytology (FNAC) for Chinese Patients With Acral and Cutaneous Melanoma: Accuracy and Safety Analysis From a Single Institution.
Yang L; Sun W; Xu Y; Zhang X; Wang S; Wang C; Chen Y
Front Oncol; 2020; 10():1724. PubMed ID: 33194572
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
28. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population.
Li C; Liu J; Jiang L; Xu J; Ren A; Lin Y; Yao G
Medicine (Baltimore); 2021 Feb; 100(8):e24840. PubMed ID: 33663104
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
Huang R; Shen G; Ren Y; Zheng K; Wang J; Shi Y; Yin JC; Qin L; Zhang G; Zhao M; Su X; Li L; Wang F; Shao Y; Liu B; Zou Z
J Transl Med; 2023 Feb; 21(1):78. PubMed ID: 36739402
[TBL] [Abstract][Full Text] [Related]
30. Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
Cho KK; Cust AE; Foo YM; Long GV; Menzies AM; Eslick GD
Melanoma Res; 2021 Oct; 31(5):482-486. PubMed ID: 34433196
[TBL] [Abstract][Full Text] [Related]
31. Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis.
Kolla AM; Vitiello GA; Friedman EB; Sun J; Potdar A; Daou H; Farrow NE; Farley CR; Vetto JT; Han D; Tariq M; Beasley GM; Contreras CM; Lowe M; Zager JS; Osman I; Berman RS; Liebman TN; Stein JA; Lee AY
Cancer Control; 2021; 28():10732748211053567. PubMed ID: 34752172
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
33. Appraisal of clinicopathological prognosticators in advanced acral lentiginous melanoma with characterization of PD-L1 and CD8/CD4 immunoprofiles.
Chuang IC; Jang CS
Jpn J Clin Oncol; 2022 Sep; 52(9):975-981. PubMed ID: 35662346
[TBL] [Abstract][Full Text] [Related]
34. Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression.
Massi D; Franchi A; Borgognoni L; Reali UM; Santucci M
Cancer; 1999 Mar; 85(5):1067-76. PubMed ID: 10091790
[TBL] [Abstract][Full Text] [Related]
35. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
Di Carlo V; Stiller CA; Eisemann N; Bordoni A; Matz M; Curado MP; Daubisse-Marliac L; Valkov M; Bulliard JL; Morrison D; Johnson C; Girardi F; Marcos-Gragera R; Šekerija M; Larønningen S; Sirri E; Coleman MP; Allemani C;
Br J Dermatol; 2022 Sep; 187(3):364-380. PubMed ID: 35347700
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of CCNE1 copy number gain in acral melanoma patients.
Wu X; Yan J; Yu J; Cheng Z; Guo Q; Kong Y; Guo J
Melanoma Res; 2021 Aug; 31(4):352-357. PubMed ID: 33965974
[TBL] [Abstract][Full Text] [Related]
37. Treatment and outcomes of melanoma in acral location in Korean patients.
Roh MR; Kim J; Chung KY
Yonsei Med J; 2010 Jul; 51(4):562-8. PubMed ID: 20499423
[TBL] [Abstract][Full Text] [Related]
38. Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial.
Mao L; Ding Y; Bai X; Sheng X; Dai J; Chi Z; Cui C; Kong Y; Fan Y; Xu Y; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Guo J; Zhang X; Si L
Front Oncol; 2021; 11():720044. PubMed ID: 34504796
[TBL] [Abstract][Full Text] [Related]
39. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.
Si L; Zhang X; Shu Y; Pan H; Wu D; Liu J; Mao L; Wang X; Wen X; Gu Y; Zhu L; Lan S; Cai X; Diede SJ; Dai H; Niu C; Li J; Guo J
Front Immunol; 2022; 13():882471. PubMed ID: 36304457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
